Mark Shearman - Dec 22, 2021 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, Chief Scientific Officer
Signature
/s/ Mark S. Shearman
Stock symbol
EDIT
Transactions as of
Dec 22, 2021
Transactions value $
$0
Form type
4
Date filed
12/23/2021, 03:10 PM
Previous filing
Jun 16, 2021
Next filing
Feb 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +9.08K +27.78% $0.00 41.8K Dec 22, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 14, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 14, 2022, subject to continued service.